Intra-Cellular Therapies Inc
ITCI·Stocks·Pharmaceuticals Major·United States·Nasdaq·USD
Price
$132.01
Today
+0.0%
YTD
+0.2%
About
The biopharmaceutical company Intra-Cellular Therapies operates primarily within the US. The company develops novel drugs for treating neurologic and neuropsychiatric diseases, as well as other disorders of the central nervous system. Headquartered in New York, the company was founded in 2002 and uses the ITCI ticker on the NASDAQ GS stock market. Track ITCI share price movements easily using your eToro watchlist.
Price chart
Closing price history for ITCI (1D candles).
Open positions
Current open positions for this instrument from your live portfolio.
Open positions
0
Unrealized return
+0.0%
No open positions exist for this instrument at the moment.
Financial insights
Valuation
P/E (TTM)-182.70
P/S (TTM)20.55
P/B (TTM)12.20
Market cap$14.05B
Cap tierLarge-cap
Industry avg P/E-7.42
Profitability
Gross margin91.63%
EBIT margin-17.14%
Net margin-8.48%
ROE-8.58%
ROA-7.13%
Earnings & Revenue
Revenue (TTM)$680.85M
Revenue growth (1Y)+46.6%
EPS (TTM)-$0.72
Free cash flow$-73.50M
Total debt$16.98M
Dividends & Risk
Dividend rate$0.00
Dividend yield0.00%
Beta (5Y)0.54
Employees860
Next earnings8 May '25
Trade history
Closed trades
0
Realized return
+0.0%
No stored closed trades exist for this instrument yet.